Search

Your search keyword '"Faezeh Izzadifar-Legrand"' showing total 2 results
Start Over Author "Faezeh Izzadifar-Legrand"
2 results on '"Faezeh Izzadifar-Legrand"'

1. Improved Outcome in Young Children Compared to Adolescents and Adults After Allogeneic Hematopoietic Stem Cell Transplant for Acute Myeloid Leukemia: a Retrospective Study From Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC) (SFGM-TC)

Author

Cécile POCHON, Marie Detrait, Jean-Hugues Dalle, Gérard Michel, Nathalie Dhédin, Yves Chalandon, Eolia Brissot, Edouard Forcade, Anne Sirvent, Faezeh Izzadifar-Legrand, Mauricette Michallet, Cécile Renard, Ibrahim Yakoub-Agha, Fanny Gonzales, Jacques- Olivier Bay, Justyna Kanold, Jérome Cornillon, Claude Eric Bulabois, Marie Angoso, Stéphanie Nguyen, Hélène Labussière-Wallet, Patrice Chevallier, Fanny Rialland, Ali Bazarbachi, Yves Beguin, Anne Huynh, Anne-Lise Ménard, Pascale Schneider, Bénédicte Neven, Catherine Paillard, Nicole Raus, Eliane Albuisson, Thomas Remen, and Marie-Thérèse Rubio

Abstract

Background: There are currently few data on the outcome of acute myeloid leukemia (AML) in adolescents and young adults (AYAs) after allogeneic HSCT. The aim of this study is to describe the outcome and its specific risk factors for children, AYAs and adults after a first allogeneic HSCT for AML. Methods: In this retrospective study, we compared the outcome of AML patients receiving a first allogeneic HSCT between 2005 and 2017 according to their age at transplantation’s time: children (Results: With a median follow-up of 4.37 years (min-max 0.18 – 14.73 years), the probability of 2 year-overall survival (OS) was 71.4% in children, 61.1% in AYAs and 62.9% in adults (p=0.0009 for intergroup difference). Both relapse and non-relapse mortality (NRM) Cumulative Incidence (CI) estimated at 2 years were different between the age groups (30.8% for children, 35.2% for AYAs and 29.4% for adults - p=0.0254, and 7.0% for children, 10.6% for AYAs and 14.2% for adults, pConclusion: Age is an independent risk factor for NRM and extensive chronic GVHD. This study suggests that AYAs AML patients should be treated with chemotherapy-based MAC regimen and bone marrow as stem cells source.

Published
2021
Full Text
View/download PDF

2. Improved outcome in children compared to adolescents and young adults after allogeneic hematopoietic stem cell transplant for acute myeloid leukemia: a retrospective study from the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC)

Author

Marie Angoso, Yves Chalandon, Anne Huynh, Justyna Kanold, Thomas Remen, Cécile Pochon, Anne Sirvent, Eolia Brissot, Faezeh Izzadifar-Legrand, Yves Beguin, Edouard Forcade, Bénédicte Neven, Stéphanie Nguyen, Eliane Albuisson, Marie-Thérèse Rubio, Patrice Chevallier, Marie Balza, Mauricette Michallet, Anne-Lise Ménard, Fanny Rialland, Marie Y Detrait, Nicole Raus, Jean-Hugues Dalle, Cecile Renard, Fanny Gonzales, Catherine Paillard, Jacques-Olivier Bay, Claude Eric Bulabois, Gérard Michel, Pascale Schneider, Ibrahim Yakoub-Agha, Nathalie Dhedin, Jérôme Cornillon, Ali Bazarbachi, Service d'Oncologie Pédiatrique [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Service d'Hématologie [CHRU Nancy], Service d'Hématologie Biologique [Hôpital Robert Debré, Paris], AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital de la Timone [CHU - APHM] (TIMONE), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpitaux Universitaires de Genève (HUG), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Bordeaux [Bordeaux], Hôpital Arnaud de Villeneuve [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre Léon Bérard [Lyon], Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Clermont-Ferrand, CHU Estaing [Clermont-Ferrand], Institut de Cancérologie Lucien Neuwirth, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre Hospitalier Universitaire [Grenoble] (CHU), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Centre hospitalier universitaire de Nantes (CHU Nantes), American University of Beirut [Beyrouth] (AUB), Centre Hospitalier Universitaire de Liège (CHU-Liège), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), CHU Necker - Enfants Malades [AP-HP], Hôpital de Hautepierre [Strasbourg], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Délégation à la Recherche Clinique et à l'Innovation [CHRU Nancy] (DRCI), Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), CHU Saint-Etienne, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Gestionnaire, Hal Sorbonne Université, Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'Immunologie et de Maladies Infectieuses (CIMI), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Cancer Research, medicine.medical_specialty, Transplantation Conditioning, Adolescent, Acute myeloblastic leukemia, Graft vs Host Disease, [SDV.CAN]Life Sciences [q-bio]/Cancer, Young Adult, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Chronic GVHD, Internal medicine, medicine, Humans, Cumulative incidence, Risk factor, Young adult, Child, Children, Bone Marrow Transplantation, Retrospective Studies, Outcome, ddc:616, Hematology, Acute GVHD, business.industry, Hematopoietic Stem Cell Transplantation, Retrospective cohort study, General Medicine, medicine.disease, Adolescent and post-adolescent patients, 3. Good health, Transplantation, Leukemia, Myeloid, Acute, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Allogeneic hematopoietic stem cell transplantation, Bone marrow, business, 030215 immunology, Young adults
Abstract

Background There are currently few data on the outcome of acute myeloid leukemia (AML) in adolescents after allogeneic HSCT. The aim of this study is to describe the outcome and its specific risk factors for children, adolescents and young adults after a first allogeneic HSCT for AML. Methods In this retrospective study, we compared the outcome of AML patients receiving a first allogeneic HSCT between 2005 and 2017 according to their age at transplantation’s time: children (n = 564), adolescent and post-adolescent (APA) patients (15–25 years, n = 647) and young adults (26–40 years; n = 1434). Results With a median follow-up of 4.37 years (min–max 0.18–14.73 years), the probability of 2-year overall survival (OS) was 71.4% in children, 61.1% in APA patients and 62.9% in young adults (p = 0.0009 for intergroup difference). Both relapse and non-relapse mortality (NRM) Cumulative Incidence (CI) estimated at 2 years were different between the age groups (30.8% for children, 35.2% for APA patients and 29.4% for young adults—p = 0.0254, and 7.0% for children, 10.6% for APA patients and 14.2% for young adults, p p Conclusion Age is an independent risk factor for NRM and extensive chronic GVHD. This study suggests that APA patients with AML could be beneficially treated with a chemotherapy-based MAC regimen and bone marrow as a stem cells source.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results